FoxP3<sup>+</sup> T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets
<p dir="ltr">T Regulatory cells (Tregs) can have both protective and pathological roles. They maintain immune homeostasis and inhibit immune responses in various diseases, including cancer. Proportions of Tregs in the peripheral blood of some cancer patients increase by approximately...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | |
| منشور في: |
2020
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513558788702208 |
|---|---|
| author | Reem Saleh (3513056) |
| author2 | Eyad Elkord (5396390) |
| author2_role | author |
| author_facet | Reem Saleh (3513056) Eyad Elkord (5396390) |
| author_role | author |
| dc.creator.none.fl_str_mv | Reem Saleh (3513056) Eyad Elkord (5396390) |
| dc.date.none.fl_str_mv | 2020-10-10T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.canlet.2020.07.022 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/FoxP3_sup_sup_T_regulatory_cells_in_cancer_Prognostic_biomarkers_and_therapeutic_targets/24270307 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Oncology and carcinogenesis Cancer Tregs prognosis biomarker therapeutic target Cancer Research Center (QBRI) |
| dc.title.none.fl_str_mv | FoxP3<sup>+</sup> T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">T Regulatory cells (Tregs) can have both protective and pathological roles. They maintain immune homeostasis and inhibit immune responses in various diseases, including cancer. Proportions of Tregs in the peripheral blood of some cancer patients increase by approximately two-fold, compared to those in healthy individuals. Tregs contribute to cancer development and progression by suppressing T effector cell functions, thereby compromising tumor killing and promoting tumor growth. Highly immunosuppressive Tregs express upregulated levels of the transcription factor, Forkhead box protein P3 (FoxP3). Elevated levels of FoxP3<sup>+</sup> Tregs within the tumor microenvironment (TME) showed a positive correlation with poor prognosis in various cancer patients. Despite the success of immunotherapy, including the use of immune checkpoint inhibitors, a significant proportion of patients show low response rates as a result of primary or acquired resistance against therapy. Some of the mechanisms which underlie the development of therapy resistance are associated with Treg suppressive function. In this review, we describe Treg contribution to cancer development/progression, and the mechanisms of Treg-mediated immunosuppression. We discuss the prognostic significance of FoxP3<sup>+</sup> Tregs in different cancers and their potential use as prognostic biomarkers. We also describe potential therapeutic strategies to target Tregs in combination with other types of immunotherapies aiming to overcome tumor resistance and improve clinical outcomes in cancer patients. Overall, understanding the prognostic significance of FoxP3<sup>+</sup> Tregs in various cancers and their contribution to therapy resistance could help in the development of more effective targeted therapeutic strategies to enhance the clinical outcomes in cancer patients.</p><h2>Other Information</h2><p dir="ltr">Published in: Cancer Letters<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.canlet.2020.07.022" target="_blank">https://dx.doi.org/10.1016/j.canlet.2020.07.022</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_0750ea045b6c8bc468c8935febebceb4 |
| identifier_str_mv | 10.1016/j.canlet.2020.07.022 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/24270307 |
| publishDate | 2020 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | FoxP3<sup>+</sup> T regulatory cells in cancer: Prognostic biomarkers and therapeutic targetsReem Saleh (3513056)Eyad Elkord (5396390)Biomedical and clinical sciencesOncology and carcinogenesisCancerTregsprognosisbiomarkertherapeutic targetCancer Research Center (QBRI)<p dir="ltr">T Regulatory cells (Tregs) can have both protective and pathological roles. They maintain immune homeostasis and inhibit immune responses in various diseases, including cancer. Proportions of Tregs in the peripheral blood of some cancer patients increase by approximately two-fold, compared to those in healthy individuals. Tregs contribute to cancer development and progression by suppressing T effector cell functions, thereby compromising tumor killing and promoting tumor growth. Highly immunosuppressive Tregs express upregulated levels of the transcription factor, Forkhead box protein P3 (FoxP3). Elevated levels of FoxP3<sup>+</sup> Tregs within the tumor microenvironment (TME) showed a positive correlation with poor prognosis in various cancer patients. Despite the success of immunotherapy, including the use of immune checkpoint inhibitors, a significant proportion of patients show low response rates as a result of primary or acquired resistance against therapy. Some of the mechanisms which underlie the development of therapy resistance are associated with Treg suppressive function. In this review, we describe Treg contribution to cancer development/progression, and the mechanisms of Treg-mediated immunosuppression. We discuss the prognostic significance of FoxP3<sup>+</sup> Tregs in different cancers and their potential use as prognostic biomarkers. We also describe potential therapeutic strategies to target Tregs in combination with other types of immunotherapies aiming to overcome tumor resistance and improve clinical outcomes in cancer patients. Overall, understanding the prognostic significance of FoxP3<sup>+</sup> Tregs in various cancers and their contribution to therapy resistance could help in the development of more effective targeted therapeutic strategies to enhance the clinical outcomes in cancer patients.</p><h2>Other Information</h2><p dir="ltr">Published in: Cancer Letters<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.canlet.2020.07.022" target="_blank">https://dx.doi.org/10.1016/j.canlet.2020.07.022</a></p>2020-10-10T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.canlet.2020.07.022https://figshare.com/articles/journal_contribution/FoxP3_sup_sup_T_regulatory_cells_in_cancer_Prognostic_biomarkers_and_therapeutic_targets/24270307CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/242703072020-10-10T00:00:00Z |
| spellingShingle | FoxP3<sup>+</sup> T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets Reem Saleh (3513056) Biomedical and clinical sciences Oncology and carcinogenesis Cancer Tregs prognosis biomarker therapeutic target Cancer Research Center (QBRI) |
| status_str | publishedVersion |
| title | FoxP3<sup>+</sup> T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets |
| title_full | FoxP3<sup>+</sup> T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets |
| title_fullStr | FoxP3<sup>+</sup> T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets |
| title_full_unstemmed | FoxP3<sup>+</sup> T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets |
| title_short | FoxP3<sup>+</sup> T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets |
| title_sort | FoxP3<sup>+</sup> T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets |
| topic | Biomedical and clinical sciences Oncology and carcinogenesis Cancer Tregs prognosis biomarker therapeutic target Cancer Research Center (QBRI) |